Evotec invests in sustainable operations at Milton Park through the Dorothy Crowfoot Hodgkin Campus
Life science company and Advanced Oxford member, Evotec, has revealed plans to significantly reduce the CO2 emissions of its site at Milton Park, a science, technology and business community in Oxfordshire – Milton Park is also an Advanced Oxford member. The project will help to achieve Evotec’s carbon neutral targets.
Expansion also creating 125 new scientific jobs
The fit-out of the firm’s latest premises on the Park, is set to be complete in Summer 2022 and will accommodate new state-of-the-art biology laboratories, as well as a conference centre, a range of collaborative workspaces and meeting rooms and a 100-seat restaurant for Evotec employees. To support its continued growth, Evotec will also be creating 125 new scientific jobs.
State-of-the-art facility will reduce annual emissions by 800 metric tons of CO2 per annum
At Evotec’s Milton Park facility – named the Dorothy Crowfoot Hodgkin Campus in commemoration of the British Nobel Prize winning chemist – the company is investing in energy-efficient operating methods. Air source heat pumps will replace traditional gas boilers and electric coolers and a demand-based laboratory ventilation system will be introduced, as well as the installation of low energy lighting and appliances. Evotec expects the plans will reduce emissions by approximately 800 metric tons of CO2 per year, the equivalent of over 970,000 worth of smartphone batteries.
Dr Christophe Muller, Global Head of Business Development and Evotec’s Site Head at Milton Park, said: “Our Dorothy Crowfoot Hodgkin Campus at Milton Park is one of Evotec’s most important and fast-growing fully integrated research and development centres. We’ve expanded our facility presence at the Park by over 40% in the last three years and have in excess of 700 employees across all major scientific disciplines required to research and develop drugs.
“We’re keen to ensure that sustainability is front and centre of what we do and have therefore invested in state-of-the-art heating and air flow technologies into our new developments at Milton Park. This will reduce our CO2 emissions in line with our internal targets as well as making our site a great and inspirational place to work.”
Philip Campbell, Commercial Director at Milton Park, said: “It’s great to see such a prominent building at Milton Park become a flagship hub for Evotec to showcase their innovative work. It’s also testament to the strong demand from the global health and life science sectors looking to be based in Oxfordshire with the creation of 125 new jobs.
“Our development team is busy working on plans for more science space at Milton Park and we look forward to revealing more on this shortly.”
About Milton Park
Milton Park is a dynamic science and technology park in Oxfordshire and one of the largest in Europe. It is a collaborative working environment and a welcoming community that fuels innovation and sustainable growth for more than 250 businesses and 9,000 people.
Its primary responsibility is to its customers with a duty to create a home for dynamic businesses, small or large, thanks to an inspiring landscape, unrivalled connectivity, and welcome humanity.
For further information, please visit: https://www.miltonpark.co.uk/
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow Evotec on Twitter @Evotec and LinkedIn.
